TY - JOUR
T1 - Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma
AU - Pfannenberg, Christina
AU - Aschoff, Philip
AU - Schanz, Sandra
AU - Eschmann, Susanne M.
AU - Plathow, Christian
AU - Eigentler, Thomas K.
AU - Garbe, Claus
AU - Brechtel, Klaus
AU - Vonthein, Reinhard
AU - Bares, Roland
AU - Claussen, Claus D.
AU - Schlemmer, Heinz P.
PY - 2007/2
Y1 - 2007/2
N2 - The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent 18F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7% compared to 78.8% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.
AB - The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent 18F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7% compared to 78.8% for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64%) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.
UR - http://www.scopus.com/inward/record.url?scp=33846587851&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.11.014
DO - 10.1016/j.ejca.2006.11.014
M3 - Journal articles
C2 - 17224266
AN - SCOPUS:33846587851
SN - 0959-8049
VL - 43
SP - 557
EP - 564
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 3
ER -
